Medical Developments International shares on watch following Penthrox update

The Medical Developments International Ltd (ASX:MVP) share price will be on watch today after the release of a Penthrox update…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.

a woman

What is Penthrox?

Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.

It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.

In recent times the company has been looking at expanding its use, hence today's announcement.

What did Medical Developments International announce?

This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.

This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.

The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.

The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.

Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.

The company's CEO, John Sharman, was delighted with the study results.

He said: "We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Dividend Investing

8% yield: The ASX is getting a new dividend stock that pays out monthly

This soon-to-be stock has averaged an 8% yield since 2016...

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today

These shares are having a good finish to the week. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why DroneShield, Hub24, Syrah, and Weebit Nano shares are sinking today

These shares are ending the week in the red. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Market News

This small-cap ASX share could rise 60%

This small cap could be heading meaningfully higher according to Bell Potter.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Healthcare Shares

Up 2,075% in a year, why is the 4DMedical share price rocketing again on Friday?

Investors just sent 4DMedical shares surging another 20% on Friday. But why?

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Materials Shares

Is this ASX iron ore stock a better buy than Fortescue?

Bell Potter thinks this stock could rise 90%.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Share Market News

5 things to watch on the ASX 200 on Friday

It looks set to be a tough finish to the week for Aussie investors.

Read more »